These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8998950)
41. Optimization issues in physiological toxicokinetic modeling: a case study with benzene. Woodruff TJ; Bois FY Toxicol Lett; 1993 Aug; 69(2):181-96. PubMed ID: 8212060 [TBL] [Abstract][Full Text] [Related]
42. Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model. Li J; Guo HF; Liu C; Zhong Z; Liu L; Liu XD Clin Pharmacokinet; 2015 Feb; 54(2):179-93. PubMed ID: 25316573 [TBL] [Abstract][Full Text] [Related]
43. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. Yang X; Doerge DR; Teeguarden JG; Fisher JW Toxicol Appl Pharmacol; 2015 Dec; 289(3):442-56. PubMed ID: 26522835 [TBL] [Abstract][Full Text] [Related]
44. Separating uncertainty and physiological variability in human PBPK modelling: The example of 2-propanol and its metabolite acetone. Huizer D; Oldenkamp R; Ragas AM; van Rooij JG; Huijbregts MA Toxicol Lett; 2012 Oct; 214(2):154-65. PubMed ID: 22955064 [TBL] [Abstract][Full Text] [Related]
45. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. Rhee SJ; Chung H; Yi S; Yu KS; Chung JY Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774 [TBL] [Abstract][Full Text] [Related]
46. Parameter sensitivity and uncertainty of the forest carbon flux model FORUG: a Monte Carlo analysis. Verbeeck H; Samson R; Verdonck F; Lemeur R Tree Physiol; 2006 Jun; 26(6):807-17. PubMed ID: 16510397 [TBL] [Abstract][Full Text] [Related]
47. An introduction to the use of physiologically based pharmacokinetic models in risk assessment. Bailer AJ; Dankovic DA Stat Methods Med Res; 1997 Dec; 6(4):341-58. PubMed ID: 9447653 [TBL] [Abstract][Full Text] [Related]
48. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. Tan YM; Liao KH; Clewell HJ J Expo Sci Environ Epidemiol; 2007 Nov; 17(7):591-603. PubMed ID: 17108893 [TBL] [Abstract][Full Text] [Related]
49. Bayesian population physiologically-based pharmacokinetic model for robustness evaluation of withdrawal time in tilapia aquaculture administrated to florfenicol. Lin HC; Chen WY Ecotoxicol Environ Saf; 2021 Mar; 210():111867. PubMed ID: 33387907 [TBL] [Abstract][Full Text] [Related]
52. PBPK model-based gender-specific risk assessment of N-nitrosodimethylamine (NDMA) using human biomonitoring data. Kang DW; Kim JH; Choi GW; Cho SJ; Cho HY Arch Toxicol; 2024 Oct; 98(10):3269-3288. PubMed ID: 39096368 [TBL] [Abstract][Full Text] [Related]
53. Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: Cattle and swine. Lin Z; Li M; Wang YS; Tell LA; Baynes RE; Davis JL; Vickroy TW; Riviere JE J Vet Pharmacol Ther; 2020 Sep; 43(5):385-420. PubMed ID: 32270548 [TBL] [Abstract][Full Text] [Related]
54. Modeling interindividual variation in physiological factors used in PBPK models of humans. Price PS; Conolly RB; Chaisson CF; Gross EA; Young JS; Mathis ET; Tedder DR Crit Rev Toxicol; 2003; 33(5):469-503. PubMed ID: 14594104 [TBL] [Abstract][Full Text] [Related]
55. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937 [TBL] [Abstract][Full Text] [Related]
56. Use of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors. Frederick CB; Lomax LG; Black KA; Finch L; Scribner HE; Kimbell JS; Morgan KT; Subramaniam RP; Morris JB Toxicol Appl Pharmacol; 2002 Aug; 183(1):23-40. PubMed ID: 12217639 [TBL] [Abstract][Full Text] [Related]
58. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. O'Hagan A; Stevenson M; Madan J Health Econ; 2007 Oct; 16(10):1009-23. PubMed ID: 17173339 [TBL] [Abstract][Full Text] [Related]
59. Monte Carlo uncertainty analysis of a diffusion model for the assessment of halogen gas exposure during dosing of brominators. Shade WD; Jayjock MA Am Ind Hyg Assoc J; 1997 Jun; 58(6):418-24. PubMed ID: 9183836 [TBL] [Abstract][Full Text] [Related]
60. A physiologically based pharmacokinetic model for the oxime TMB-4: simulation of rodent and human data. Sterner TR; Ruark CD; Covington TR; Yu KO; Gearhart JM Arch Toxicol; 2013 Apr; 87(4):661-80. PubMed ID: 23314320 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]